TPG Capital Acquires Beaver-Visitec International

Experienced Healthcare Investor to Partner with Leading Ophthalmology Platform

FORT WORTH, Texas & SAN FRANCISCO--()--TPG Capital, the North American- and European-focused private equity fund of leading global alternative asset firm TPG, today announced it has entered into a definitive agreement to purchase Beaver-Visitec International (“BVI” or the “Company”) from RoundTable Healthcare Partners (“RoundTable”). BVI is a leading global developer, manufacturer, and marketer of specialized surgical devices for the ophthalmic marketplace. The sale is expected to close during the third quarter. Additional terms of the transaction were not disclosed.

The investment in BVI reflects TPG’s strategy of identifying exceptional companies and management teams across the healthcare industry. Since 2007, TPG has invested more than $8 billion in its healthcare portfolio across the platform.

“TPG has a long history of partnering with leading companies in the healthcare sector that hold significant growth potential,” said Jeffrey Rhodes, Partner at TPG. “We’ve worked with a wide variety of companies, from blood transfusion therapies business Fenwal to drug maker Par Pharmaceutical, to discover and invest in new opportunities.”

BVI was created in 2010 through the combination of three separate ophthalmic product businesses from Becton Dickinson, Medtronic, and Aspen Surgical. The Company operates two state-of-the-art manufacturing plants in Waltham, MA and Bidford, U.K. BVI brings together high-quality brands, including Beaver® blades, Visitec® cannulae and instruments, Merocel® and Weck-Cel® ophthalmic fluid management products, and Wet-Field Eraser® electrosurgery products. These products serve a wide variety of ophthalmic surgeries, including cataract, refractive, oculoplastic, and vitreoretinal sub-specialty procedures.

“BVI’s industry-leading products and brands, strong commitment to quality, and focus on enabling ophthalmic surgeons to achieve the best patient outcomes position the company well for continued success and growth,” said John Schilling, Partner at TPG. “We look forward to working with the BVI team, building on the strong foundation they have established, and creating a leading global ophthalmology platform together.”

Tom Kapfer, Chief Executive Officer of BVI, added, “RoundTable was invaluable in helping us execute on the vision of combining separate ophthalmic businesses into a well-run, global organization. Their support and resources have helped us accelerate organic growth initiatives and complete strategic acquisitions. We look forward to our new partnership with TPG and continuing to grow our business.”

TPG’s healthcare investments have spanned disciplines and geographies around the world, including pharmaceutical services leaders such as IMS, Quintiles and EnvisionRX; blood transfusion therapy and diagnostics manufacturers Fenwal and Immucor; orthopedic device company Biomet; providers across the globe such as Surgical Care Affiliates, IASIS, Parkway, Chindex and Manipal Hospitals; and pharmaceutical manufacturers Adare, Aptalis and Par Pharmaceutical.

Deutsche Bank Securities Inc., Guggenheim Securities, LLC, RBC Capital Markets and UBS Investment Bank acted as financial advisors to TPG. UBS Investment Bank, Deutsche Bank Securities Inc., Antares Holdings and RBC Capital Markets provided committed financing to TPG. Ropes & Gray LLP served as legal counsel to TPG.

About TPG

TPG is a leading global private investment firm founded in 1992 with over $70 billion of assets under management and offices in Austin, Beijing, Dallas, Fort Worth, Hong Kong, Houston, Istanbul, London, Luxembourg, Melbourne, Moscow, Mumbai, New York, San Francisco, São Paulo, Singapore, and Tokyo. TPG’s investment platforms are across a wide range of asset classes, including private equity, growth venture, real estate, credit, and public equity. TPG aims to build dynamic products and options for its investors while also instituting discipline and operational excellence across the investment strategy and performance of their portfolio. For more information, visit www.tpg.com.

About Beaver-Visitec International, Inc.

Headquartered in Waltham, Massachusetts, USA, Beaver-Visitec International develops, manufactures and markets ophthalmic and other specialty microsurgical products. Beaver-Visitec distributes products in over 90 countries worldwide and operates manufacturing facilities in Waltham, MA, USA and Bidford on Avon, U.K. Beaver-Visitec offers products and services for all aspects of Ophthalmic Surgery, including cataract, refractive, oculoplastic, and vitreoretinal sub-specialties as well as other specialty microsurgery procedures. More information about Beaver-Visitec International can be found at www.beaver-visitec.com.

Contacts

TPG External Affairs
Erika White, +1 415-743-1550
ewhite@tpg.com

Release Summary

TPG Capital today announced it has entered into a definitive agreement to purchase Beaver-Visitec International.

Contacts

TPG External Affairs
Erika White, +1 415-743-1550
ewhite@tpg.com